Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Danny Rischin, Nikhil I. Khushalani, Chrysalyne D. Schmults, Alexander David Guminski, Anne Lynn S. Chang, Karl D. Lewis, Annette May Ling Lim, Leonel Fernando Hernandez-Aya, Brett Gordon Maxwell Hughes, Dirk Schadendorf, Axel Hauschild, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Zhen Chen, Emmanuel Okoye, Israel Lowy, Matthew G. Fury, Michael Robert Migden
Institutions: Peter MacCallum Cancer Centre, Moffitt Cancer Center, Brigham and Women's Hospital, Harvard University, Royal North Shore Hospital, Stanford Medicine, Stanford University, University of Colorado Anschutz, University of Colorado Denver, Washington University in St. Louis, The University of Queensland, Royal Brisbane and Women's Hospital, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University Hospital Schleswig-Holstein, Regeneron (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032360909